Outlook Therapeutics, Inc. (OTLK) shares are gaining more than 40 percent on Friday morning trade after the company received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP Bevacizumab ophthalmic formulation called ONS-5010.
This formulation is intended to treat wet age-related macular degeneration or wet AMD in the European Union.
The company said in a statement, "Positive opinion serves as a basis for final decision for potential authorization from the European Commission (EC), expected within 67 days"
Currently, shares are at $9.87, up 40 percent from the previous close of $7.04 on a volume of 15,538,255.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.